Technion – Israel Institute of Technology

STRATA Skin Science Announces Leadership Change

Retrieved on: 
Monday, October 30, 2023
Psoriasis, Vitiligo, STRATA, Technion – Israel Institute of Technology, Bachelor of Science, Intellectual property, Doctor of Philosophy, MBA, Growth, Acne, Marketing, Summa, Cornell University, SSKN, Master of Science, Patient, Management

HORSHAM, Pa., Oct. 30, 2023 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing and marketing innovative products for the treatment of dermatologic conditions, today announced that the Board of Directors and Bob Moccia have mutually agreed that Mr. Moccia will step down as the Company’s Chief Executive Officer (CEO) and member of the Board, as of October 30, 2023. Dr. Dolev Rafaeli has been named the new Vice-Chairman, President and Chief Executive Officer.

Key Points: 
  • Dr. Dolev Rafaeli has been named the new Vice-Chairman, President and Chief Executive Officer.
  • Additionally, from 2006 to 2017, he served as the President and CEO of Radiancy Inc., a subsidiary of PhotoMedex.
  • “On behalf of the Board, I would like to thank Bob Moccia for his dedicated leadership and invaluable contributions during his time at the helm of STRATA,” stated Dr. Uri Geiger, Chairman of the Board.
  • I take great pride in contributing to this outstanding team and look forward to STRATA’s future successes.”

Synaptogenix Acquires Significant Stake in Cannasoul Analtyics Ltd. Co-founded by The Technion - Israel Institute of Technology

Retrieved on: 
Thursday, November 2, 2023
Cannabis, Science, MIT, Therapy, Intellectual property, Cannabinoid, University of Freiburg Faculty of Biology, Research, Technology Development Foundation of Turkey, Sleep, Laboratory, Partnership, Leukemia, Nobel Prize, Epilepsy, Patient, Massachusetts Institute of Technology, Pharmaceutical industry, Biology, Technion – Israel Institute of Technology

NEW YORK, Nov. 2, 2023 /PRNewswire/ -- Synaptogenix, Inc. (Nasdaq: SNPX) ("Synaptogenix" or the "Company"), an emerging biopharmaceutical company developing therapeutics for neurodegenerative disorders, today announced a new partnership with Cannasoul Analytics Ltd. ("Cannasoul") in support of research and development of pharmaceutical therapeutics. Cannasoul is founded by the Technion Research & Development Foundation ("TRDF"), the commercialization arm of The Technion – Israel Institute of Technology ("The Technion"), and world-renowned cannabis key opinion leader and researcher Professor Dedi Meiri from The Technion.

Key Points: 
  • Cannasoul is founded by the Technion Research & Development Foundation ("TRDF"), the commercialization arm of The Technion – Israel Institute of Technology ("The Technion"), and world-renowned cannabis key opinion leader and researcher Professor Dedi Meiri from The Technion.
  • Professor Meiri and The Technion founded Cannasoul in 2018 for the development of cannabinoid-based and other therapeutics for various indications and vertical markets.
  • Cannasoul has developed technology in large disease markets including leukemia ($12.7B by 20281), epilepsy ($14.7B by 20332), and sleep disorders ($73.5B by 20323).
  • "Cannasoul is pleased to welcome Synaptogenix as a key partner in our development of groundbreaking therapeutics derived from natural compounds.

Eli Israeli Joins Odysight.ai as Chief Technology Officer

Retrieved on: 
Monday, October 23, 2023
Aircraft, IAI, CBM, Predictive maintenance, TEL, Tel Aviv University, Bachelor of Education, History, MALE, Systems engineering, Bachelor of Science, Directorate of Defense Trade Controls, PDM, Customer success, OTCQB, Program management, Artificial intelligence, Senior, Ministry, Aviation, Transport, Intelligence, Master of Science, AI, Defense, Maintenance (technical), Management, Jet fuel, Technion – Israel Institute of Technology

OMER, Israel, Oct. 23, 2023 (GLOBE NEWSWIRE) -- Odysight.ai Inc. (OTCQB: SCTC), a leading provider of visual based predictive maintenance (PdM) and condition-based monitoring (CBM) solutions, announced today the appointment of Eli Israeli as Chief Technology Officer.

Key Points: 
  • OMER, Israel, Oct. 23, 2023 (GLOBE NEWSWIRE) -- Odysight.ai Inc. (OTCQB: SCTC), a leading provider of visual based predictive maintenance (PdM) and condition-based monitoring (CBM) solutions, announced today the appointment of Eli Israeli as Chief Technology Officer.
  • With his wealth of experience Mr. Israeli will be pivotal in helping shape and steer the Company's technological landscape and drive innovation.
  • As CTO, Mr. Israeli will oversee the Company’s comprehensive technology strategy which revolves around ushering in pioneering Predictive Maintenance (PdM) and Condition-Based Monitoring (CBM) solutions, powered by Odysight.ai's cutting-edge visualization and AI platform.
  • Eli Israeli's illustrious career boasts a history of leadership positions, including his role as the Chief Technology Officer at Gadfin, where he spearheaded the development and execution of Gadfin's technology strategy, aligning these efforts with overarching business objectives and leading the charge in technology development.

Mana.bio Advances AI-Based Lipid Nanoparticle (LNP) Platform to Accelerate "Programmable Drug Delivery" for RNA and Gene Therapies

Retrieved on: 
Tuesday, October 10, 2023
Nanomedicine, Data science, Doctor of Philosophy, Machine learning, Vaccine, Yogev, TEL, RNA, LNP, EBay, AI, MD, Organization, Therapy, Cardiology, Neurology, Twist, Wolf Foundation, Cystic fibrosis, Health, Department of Chemical Engineering, Imperial College London, Biotechnology, Medicine, General partnership, Beam Therapeutics, R, Artificial intelligence, Twist Bioscience, Bayer, MIT, CRISPR, Conditional sentence, Chemical engineering, Compiler, Chemical substance, Gene editing, MIT Technology Review, IPO, Tissue, Rising Star, Institution of Chemical Engineers, Nanotechnology, Young Innovation Leaders Fellowship, Pharmaceutical industry, Biogen, Pfizer, Technion – Israel Institute of Technology

Mana.bio's integrated experimental and machine learning platform enables the discovery of smarter, faster, more precise delivery formulations to unlock the field of nucleic acid-based and genetic medicines.

Key Points: 
  • Mana.bio's integrated experimental and machine learning platform enables the discovery of smarter, faster, more precise delivery formulations to unlock the field of nucleic acid-based and genetic medicines.
  • We are encouraged by our platform's early in vivo success and for its potential to deliver breakthrough therapies for a broad range of diseases."
  • RNA-based therapies and genetic medicines offer immense potential to transform approaches to vaccines, gene editing, gene therapy and more.
  • The limitations on delivery methods have severely restricted the full therapeutic promise of RNA, CRISPR and gene therapies.

Curio Wellness Appoints Dr. David "Dedi" Meiri to its Scientific Advisory Board

Retrieved on: 
Wednesday, September 27, 2023
SAB, Curio, Biochemistry, Education, Doctor of Philosophy, Systemic disease, Alzheimer's disease, Cancer, Cannabinoid, United States Air Force Scientific Advisory Board, Research, Technion – Israel Institute of Technology, Cannabis, Health, Sleep, Rest, Pharmaceutical industry, Tel Aviv University

TIMONIUM, Md., Sept. 27, 2023 /PRNewswire/ -- Curio Wellness,  a cGMP-certified, vertically integrated cannabis company and market-leading innovator of health and wellness products, today announced that it has appointed Dr. Dedi Meiri to its Scientific Advisory Board (SAB).

Key Points: 
  • TIMONIUM, Md., Sept. 27, 2023 /PRNewswire/ -- Curio Wellness , a cGMP-certified, vertically integrated cannabis company and market-leading innovator of health and wellness products, today announced that it has appointed Dr. Dedi Meiri to its Scientific Advisory Board (SAB).
  • Dr. Meiri joins Curio's SAB with extensive education and research in the biochemistry and cannabinoid field, holding an M.Sc.
  • As part of the SAB at Curio, Dr. Meiri will use his expertise to help guide the company's innovations in scientifically-developed medicinal products derived from cannabis.
  • "I am thrilled to join the Curio Scientific Advisory Board to provide insight into a field I love.

Meatafora Advances its Mission in Bringing Cost-Efficient and Scalable Cultured Meat to the Marketplace

Retrieved on: 
Tuesday, September 19, 2023
Edible, Sale, Technion – Israel Institute of Technology, Growth, Nature Communications, TEL, FDA, Research, Agriculture

Meatafora is leveraging its newest technology to advance its mission to enter the market with a cultured meat product that is affordable, scalable, and flavorful.

Key Points: 
  • Meatafora is leveraging its newest technology to advance its mission to enter the market with a cultured meat product that is affordable, scalable, and flavorful.
  • First, Meatafora has successfully developed an oleogel fat substitute that mimics animal-derived fat, but with improved nutritional value.
  • The food tech company also produced edible and high-quality microcarriers for upscaling cultured meat production.
  • Meatafora focuses on scaling up and offering the most cost-efficient option to the marketplace.

JenaValve Appoints Shlomi Nachman to Board of Directors

Retrieved on: 
Thursday, September 14, 2023
Aortic stenosis, Technion – Israel Institute of Technology, Johnson & Johnson, Research, Economics, J&J, Chemistry, Optometry, Patient, TAVR, Ear, Arnold, AR, Electricity, Electrophysiology, Nursing, Science, Cordis, Ophthalmology

IRVINE, Calif., Sept. 14, 2023 (GLOBE NEWSWIRE) -- JenaValve Technology, Inc., developer and manufacturer of differentiated transcatheter aortic valve replacement (TAVR) systems, today announced that it has appointed Shlomi Nachman, experienced cardiovascular industry executive, to its Board of Directors.

Key Points: 
  • IRVINE, Calif., Sept. 14, 2023 (GLOBE NEWSWIRE) -- JenaValve Technology, Inc., developer and manufacturer of differentiated transcatheter aortic valve replacement (TAVR) systems, today announced that it has appointed Shlomi Nachman, experienced cardiovascular industry executive, to its Board of Directors.
  • “We are thrilled to welcome Shlomi to the JenaValve Board of Directors,” said John Kilcoyne, Chief Executive Officer.
  • “His experience as both an executive and board member across innovative cardiovascular device businesses further strengthens the operating expertise of our board.
  • Mr. Nachman stated, “I am grateful to have the opportunity to join JenaValve at such an exciting time in the company’s development.

FICO Releases First Major Global Optimization Solver for Complex “Nonlinear” Problems

Retrieved on: 
Thursday, August 31, 2023
Professional Services, Data Management, Technology, Software, Finance, Artificial Intelligence, Banking, SOCP, Cornell Tech, Operations research, Research, Constraint, Constraint programming, Information, Data science, Motion, MIP, Publication, Jacobs, Machine learning, Algorithm, FICO Xpress, QCQP, AI, FICO, LP, Cornell University, Video game, Asset management, Online shopping, Technion – Israel Institute of Technology

Analytics software leader FICO today announced the release of a true global mathematical optimization solver as part of FICO® Xpress 9.2 Optimization.

Key Points: 
  • Analytics software leader FICO today announced the release of a true global mathematical optimization solver as part of FICO® Xpress 9.2 Optimization.
  • The global optimization solver gives users a better way to tackle complex nonlinear problems in energy, pricing optimization and many other fields, and can offer guarantees about the performance of the solutions it finds.
  • FICO is the first major commercial optimization provider to release a true global mathematical solver.
  • It is impressive to see that FICO, a renowned industry leader in analytics software, is taking the pioneering initiative to introduce a global optimization solver for general mixed-integer nonlinear optimization problems.

Preeclampsia Foundation-funded Genetic Research Study Finds Two Distinct Molecular "Faces" of Preeclampsia

Retrieved on: 
Tuesday, August 29, 2023
HELLP, Pregnancy, Placenta, Rambam Health Care Campus, Fetus, Organ dysfunction, Research, MD Anderson Cancer Center, Inflammation, RNA, Doctor of Philosophy, Late-onset hypogonadism, Pre-eclampsia, HELLP syndrome, MD, Patient, Hypertension, Place of birth, Infant, Growth, Death, Gene, Disease, Pharmaceutical industry, Vaccine, Technion – Israel Institute of Technology

For this study, single-cell transcriptomic research measured tens of thousands of placental cells, one cell at a time, using single-cell RNA sequencing.

Key Points: 
  • For this study, single-cell transcriptomic research measured tens of thousands of placental cells, one cell at a time, using single-cell RNA sequencing.
  • "This is important because it means there is a real molecular basis for two forms of preeclampsia, and that treatments will need to be tailored to these distinct subtypes."
  • "For example, the role of inflammation has been well described in preeclampsia research, but not fully understood," said Zeisel.
  • "We are looking forward to the continued growth of research stemming from this important finding related to preeclampsia," said Clement Pappas.

Nevia Bio Completes a $3M Seed Round to Build a Machine Learning-Enabled Platform for Early Detection of Women-Related Diseases

Retrieved on: 
Tuesday, August 29, 2023
Neiva, Huila, Ovarian cancer, Woman, Biomarker, Chairperson, Data science, Patient, Machine learning, VCS, Diagnosis, AI, Disease, Birth control, Medical imaging, Nevia, Technion – Israel Institute of Technology

HAIFA, Israel, Aug. 29, 2023 /PRNewswire/ -- Nevia Bio (formerly Gina Life), a company developing a machine learning empowered platform for early detection of women's health indications today announced completion of a $3.1M Seed Round.

Key Points: 
  • HAIFA, Israel, Aug. 29, 2023 /PRNewswire/ -- Nevia Bio (formerly Gina Life), a company developing a machine learning empowered platform for early detection of women's health indications today announced completion of a $3.1M Seed Round.
  • This Seed round comes on the heels of a $1.9 M Pre-Seed Round which brings the company's total funding to date to $5M.
  • Ovarian cancer is detected late in the vast majority of patients resulting in poor survival rates and high cost of care, due to lack of efficient early detection methods.
  • The Nevia groundbreaking platform decodes information from women's vaginal secretions by applying Machine Learning tools to identify specific proprietary biomarkers signatures to detect the disease in its early and late stages.